Andrew W Dick1, Eli N Perencevich2, Monika Pogorzelska-Maziarz3, Jack Zwanziger4, Elaine L Larson5, Patricia W Stone6. 1. RAND Corporation, Pittsburgh, PA. Electronic address: andrewd@rand.org. 2. Divisions of General Internal Medicine and Infectious Diseases, Department of Internal Medicine University of Iowa, Carver College of Medicine and Iowa City VA Medical Center, Iowa City, IA. 3. Jefferson School of Nursing, Thomas Jefferson University, Philadelphia, PA. 4. Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL. 5. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; Center for Health Policy, School of Nursing, Columbia University, New York, NY. 6. Center for Health Policy, School of Nursing, Columbia University, New York, NY.
Abstract
BACKGROUND: Health care-associated infection (HAI) rates have fallen with the development of multifaceted infection prevention programs. These programs require ongoing investments, however. Our objective was to examine the cost-effectiveness of hospitals' ongoing investments in HAI prevention in intensive care units (ICUs). METHODS: Five years of Medicare data were combined with HAI rates and cost and quality of life estimates drawn from the literature. Life-years (LYs), quality-adjusted LYs (QALYs), and health care expenditures with and without central line-associated bloodstream infection (CLABSI) and/or ventilator-associated pneumonia (VAP), as well as incremental cost-effectiveness ratios (ICERs) of multifaceted HAI prevention programs, were modeled. RESULTS: Total LYs and QALYs gained per ICU due to infection prevention programs were 15.55 LY and 9.61 QALY for CLABSI and 10.84 LY and 6.55 QALY for VAP. Reductions in index admission ICU costs were $174,713.09 for CLABSI and $163,090.54 for VAP. The ICERs were $14,250.74 per LY gained and $23,277.86 per QALY gained. CONCLUSIONS: Multifaceted HAI prevention programs are cost-effective. Our results underscore the importance of maintaining ongoing investments in HAI prevention. The welfare benefits implied by the advantageous ICERs would be lost if the investments were suspended.
BACKGROUND: Health care-associated infection (HAI) rates have fallen with the development of multifaceted infection prevention programs. These programs require ongoing investments, however. Our objective was to examine the cost-effectiveness of hospitals' ongoing investments in HAI prevention in intensive care units (ICUs). METHODS: Five years of Medicare data were combined with HAI rates and cost and quality of life estimates drawn from the literature. Life-years (LYs), quality-adjusted LYs (QALYs), and health care expenditures with and without central line-associated bloodstream infection (CLABSI) and/or ventilator-associated pneumonia (VAP), as well as incremental cost-effectiveness ratios (ICERs) of multifaceted HAI prevention programs, were modeled. RESULTS: Total LYs and QALYs gained per ICU due to infection prevention programs were 15.55 LY and 9.61 QALY for CLABSI and 10.84 LY and 6.55 QALY for VAP. Reductions in index admission ICU costs were $174,713.09 for CLABSI and $163,090.54 for VAP. The ICERs were $14,250.74 per LY gained and $23,277.86 per QALY gained. CONCLUSIONS: Multifaceted HAI prevention programs are cost-effective. Our results underscore the importance of maintaining ongoing investments in HAI prevention. The welfare benefits implied by the advantageous ICERs would be lost if the investments were suspended.
Authors: Margaret A Dudeck; Teresa C Horan; Kelly D Peterson; Katherine Allen-Bridson; Gloria Morrell; Daniel A Pollock; Jonathan R Edwards Journal: Am J Infect Control Date: 2011-12 Impact factor: 2.918
Authors: Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder Journal: Value Health Date: 2013 Mar-Apr Impact factor: 5.725
Authors: Hugh R Waters; Roy Korn; Elizabeth Colantuoni; Sean M Berenholtz; Christine A Goeschel; Dale M Needham; Julius C Pham; Allison Lipitz-Snyderman; Sam R Watson; Patricia Posa; Peter J Pronovost Journal: Am J Med Qual Date: 2011 Sep-Oct Impact factor: 1.852
Authors: Patricia W Stone; Monika Pogorzelska-Maziarz; Carolyn T A Herzig; Lindsey M Weiner; E Yoko Furuya; Andrew Dick; Elaine Larson Journal: Am J Infect Control Date: 2014-02 Impact factor: 2.918
Authors: Deborah S Yokoe; Leonard A Mermel; Deverick J Anderson; Kathleen M Arias; Helen Burstin; David P Calfee; Susan E Coffin; Erik R Dubberke; Victoria Fraser; Dale N Gerding; Frances A Griffin; Peter Gross; Keith S Kaye; Michael Klompas; Evelyn Lo; Jonas Marschall; Lindsay Nicolle; David A Pegues; Trish M Perl; Kelly Podgorny; Sanjay Saint; Cassandra D Salgado; Robert A Weinstein; Robert Wise; David Classen Journal: Infect Control Hosp Epidemiol Date: 2008-10 Impact factor: 3.254
Authors: Werner A Scherbaum; Gordon Goodall; Katrina M Erny-Albrecht; Massimo Massi-Benedetti; Erland Erdmann; William J Valentine Journal: Cost Eff Resour Alloc Date: 2009-05-05
Authors: Ron Balczon; K Adam Morrow; Chun Zhou; Bradley Edmonds; Mikhail Alexeyev; Jean-Francois Pittet; Brant M Wagener; Stephen A Moser; Silas Leavesley; Xiangming Zha; Dara W Frank; Troy Stevens Journal: FASEB J Date: 2017-03-17 Impact factor: 5.191
Authors: Daniel E Abbott; Grace Martin; David A Kooby; Nipun B Merchant; Malcolm H Squires; Shishir K Maithel; Sharon M Weber; Emily R Winslow; Clifford S Cho; David J Bentrem; Hong Jin Kim; Charles R Scoggins; Robert C Martin; Alexander A Parikh; William G Hawkins; Syed A Ahmad Journal: HPB (Oxford) Date: 2016-03-02 Impact factor: 3.647
Authors: David W Hutton; Sarah L Krein; Sanjay Saint; Nicholas Graves; Ajay Kolli; Raymond Lynem; Lona Mody Journal: J Am Geriatr Soc Date: 2018-02-28 Impact factor: 5.562
Authors: Teryl K Nuckols; Emmett Keeler; Sally C Morton; Laura Anderson; Brian Doyle; Marika Booth; Roberta Shanman; Jonathan Grein; Paul Shekelle Journal: JAMA Intern Med Date: 2016-12-01 Impact factor: 21.873